Itruvone
| Clinical data | |
|---|---|
| Other names | PH10A; PH10 NS[1] |
| Routes of administration | Intranasal |
| Legal status | |
| Legal status |
|
PH10 is a purported vomeropherine that is under development by VistaGen Therapeutics as a nasal spray for the treatment of major depressive disorder.[2][3][4][5]
See also
References
- ^ "PH-10 Nasal Spray". AdisInsight. Springer Nature Switzerland AG.
- ^ "VistaGen Therapeutics Acquires Worldwide Rights to Develop and Commercialize PH10, a First-in-Class Intranasally Administered Neuroactive Steroid with Rapid-onset Antidepressant Effects for Major Depressive Disorder Demonstrated in Phase 2a Study :: VistaGen Therapeutics, Inc. (VTGN)". VistaGen Therapeutics, Inc. Retrieved 2019-12-19.
- ^ "Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more". www.bizjournals.com. San Francisco Business Times. October 29, 2018. Retrieved 20 July 2020.
{{cite web}}: CS1 maint: url-status (link) - ^ Liebowitz MR, Nicolini H, Monti L, Hanover R (2013). "PH 10 may be a new rapidly acting intranasally administered antidepressant". American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, Miami, FL.
{{cite journal}}: Cite journal requires|journal=(help) - ^ Jancin B (2013). "Novel intranasal antidepressant shows results after 1 week". Clinical Psychiatry News. Retrieved 13 January 2016.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |